Aaron Goodman

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Genome-wide sequencing of cell-free DNA enables detection of copy number alterations in cancer patients where tissue biopsy is not feasible. Mol Cancer Ther. 2021 Aug 31. Jensen TJ, Goodman AM, Ellison CK, Holden KA, Kato S, Kim L, Daniels GA, Fitzgerald K, McCarthy E, Nakashe P, Mazloom AR, Almasri E, McLennan G, Grosu DS, Eisenberg M, Kurzrock R. PMID: 34465593.
      View in: PubMed   Mentions:    Fields:    
    2. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer. 2021 Aug 25; 156:164-174. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V. PMID: 34454318.
      View in: PubMed   Mentions:    Fields:    
    3. Novel Somatic Alterations in Unicentric and Idiopathic Multicentric Castleman Disease. Eur J Haematol. 2021 Aug 24. Goodman AM, Jeong AR, Phillips A, Wang HY, Sokol ES, Cohen PR, Sicklick J, Fajgenbaum DC, Kurzrock R. PMID: 34431136.
      View in: PubMed   Mentions:    Fields:    
    4. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leuk Lymphoma. 2021 Jun 11; 1-3. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V. PMID: 34114943.
      View in: PubMed   Mentions:    Fields:    
    5. Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet. 2021 May 01; 397(10285):1620-1621. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V. PMID: 33933200.
      View in: PubMed   Mentions:    Fields:    
    6. Rosai-Dorfman-Destombes (RDD) disease presenting as palindromic rheumatism. BMC Med Imaging. 2021 Apr 15; 21(1):72. Haghighat Jahromi A, Goodman AM, Hoh CK. PMID: 33858362.
      View in: PubMed   Mentions:    Fields:    
    7. Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Netw Open. 2021 04 01; 4(4):e218084. Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V. PMID: 33909053.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol. 2021 Apr; 8(4):e299-e304. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V. PMID: 33770485.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. Eur J Cancer. 2021 May; 148:215-229. Krishnamurthy N, Goodman AM, Barkauskas DA, Kurzrock R. PMID: 33744718.
      View in: PubMed   Mentions:    Fields:    
    10. Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma. Front Oncol. 2021; 11:620435. Wang HY, Sokol ES, Goodman AM, Feldman AL, Mulroney CM. PMID: 33777766.
      View in: PubMed   Mentions:
    11. Persistent challenges with treating multiple myeloma early. Blood. 2021 01 28; 137(4):456-458. Goodman AM, Kim MS, Prasad V. PMID: 33236046.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? Clin Med Insights Oncol. 2020; 14:1179554920976366. Jeong AR, Ball ED, Goodman AM. PMID: 33447123.
      View in: PubMed   Mentions:
    13. Cutaneous intralymphatic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma arising in a patient with multiple rounds of breast implants. J Cutan Pathol. 2021 May; 48(5):659-662. Wang HY, Thorson JA, Hinds BR, Swalchick W, Parker BA, Chong A, Wallace AM, Goodman AM. PMID: 33314229.
      View in: PubMed   Mentions:    Fields:    
    14. Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Res. 2020 Dec 09; 10(1):150. Haghighat Jahromi A, Barkauskas DA, Zabel M, Goodman AM, Frampton G, Nikanjam M, Hoh CK, Kurzrock R. PMID: 33296034.
      View in: PubMed   Mentions:
    15. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw. 2020 11 02; 18(11):1460-1467. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H. PMID: 33152703.
      View in: PubMed   Mentions:    Fields:    
    16. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021 Feb 08; 39(2):154-173. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. PMID: 33125859.
      View in: PubMed   Mentions: 11     Fields:    
    17. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Ther. 2021 Jul; 21(7):849-862. Goldenson BH, Goodman AM, Ball ED. PMID: 32990476.
      View in: PubMed   Mentions: 1     Fields:    
    18. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    19. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020 12; 95(12):1553-1561. Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F, Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international . PMID: 32894785.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    20. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Mol Cancer Ther. 2020 10; 19(10):2139-2145. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. PMID: 32747422.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    21. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol Oncol. 2020 08; 14(8):1680-1694. Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R. PMID: 32530570.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus. 2020 Jul 02; 12(7):e8967. Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R. PMID: 32766009.
      View in: PubMed   Mentions:
    23. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. J Oncol Pharm Pract. 2021 Jun; 27(4):821-826. Lau KM, Saunders IM, Goodman AM. PMID: 32605497.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 2020 06 24; 9(1):1781997. Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R. PMID: 32923144.
      View in: PubMed   Mentions:
    25. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945. Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL. PMID: 32187362.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    26. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 05 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    27. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw. 2020 05; 18(5):522-536. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. PMID: 32380458.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    28. An IgA plasmacytoma: a rare and distinct form of plasmacytoma. Blood. 2020 04 23; 135(17):1505. Wang HY, Goodman AM. PMID: 32324872.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. JCO Precis Oncol. 2020; 4. Vu P, Khagi Y, Riviere P, Goodman A, Kurzrock R. PMID: 32923910.
      View in: PubMed   Mentions:
    30. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9(1):1708065. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. PMID: 32117584.
      View in: PubMed   Mentions:
    31. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 06 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    32. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. Oncologist. 2020 02; 25(2):e386-e390. Saunders IM, Goodman AM, Kurzrock R. PMID: 32043767.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):431-437.e2. Klebaner D, Koura D, Tzachanis D, Ball ED, Horwitz S, Goodman AM. PMID: 32284297.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019 10; 7(10):1570-1573. Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. PMID: 31405947.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    35. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019 Jun 18; 10(40):4018-4025. Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. PMID: 31258846.
      View in: PubMed   Mentions: 26     Fields:    
    36. Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies. J Oncol Pharm Pract. 2020 Mar; 26(2):351-360. Kim S, Namba J, Goodman AM, Nguyen T, Saunders IM. PMID: 31142232.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. . 2019 06; 18(6):1149-1157. Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. PMID: 31015311.
      View in: PubMed   Mentions:
    38. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    39. Schnitzler syndrome associated with MYD88 L265P mutation. JAAD Case Rep. 2019 Apr; 5(4):312-316. Goodman AM, Cohen PR, Li A, Hinds B, Kurzrock R. PMID: 30989098.
      View in: PubMed   Mentions:
    40. Immune Escape of AML Cells after Transplantation. N Engl J Med. 2019 03 28; 380(13):1289. Goodman AM, Kurzrock R. PMID: 30917272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2020 Jan; 26(1):193-199. Lau KM, Saunders IM, Goodman A. PMID: 30823860.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253.
      View in: PubMed   Mentions:
    43. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 2019; 8(3):1550341. Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R. PMID: 30723579.
      View in: PubMed   Mentions:
    44. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461.
      View in: PubMed   Mentions:
    45. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. . 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions:
    46. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer. 2018 10 15; 124(20):4080-4089. Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. PMID: 30204251.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    47. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018 10; 6(10):1129-1135. Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. PMID: 30194084.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    48. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. PMID: 30181172.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    49. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. PMID: 29902298.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    50. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405.
      View in: PubMed   Mentions:
    51. Erythrodermic Psoriasis in a Man with Monoclonal B-cell Lymphocytosis. Cureus. 2017 Dec 11; 9(12):e1936. Chen SX, Hinds BR, Goodman AM, Cohen PR. PMID: 29464143.
      View in: PubMed   Mentions:
    52. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    53. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. . 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386.
      View in: PubMed   Mentions:
    54. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. PMID: 28788102.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    55. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041.
      View in: PubMed   Mentions:
    56. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930.
      View in: PubMed   Mentions: 266     Fields:    Translation:Humans
    57. What are the latest advancements in acute myeloid leukemia therapy? Future Oncol. 2017 Apr; 13(10):867-871. Goodman A, Ball ED. PMID: 28266249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis. Oncology (Williston Park). 2017 02 15; 31(2):122-4, 126-8. Goodman AM, Rust M, Costello C, Ball ED. PMID: 28205192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 04; 14(4):203-220. Goodman A, Patel SP, Kurzrock R. PMID: 27805626.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    60. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. PMID: 27942391.
      View in: PubMed   Mentions:
    61. An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. Oncology (Williston Park). 2016 08 15; 30(8):705-8, 710, 712. Goodman AM, Choi M, Wang L, Kurzrock R. PMID: 27535668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Aaron's Networks
    Concepts (189)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (38)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version v3.0.0-841-gd6c3184f on PROFILES-PWEB02.

    Copyright © The Regents of the University of California